Implant-based reconstruction linked to increased risk of breast lymphomas

Published Date: 16 Aug 2025

Columbia University investigators report an increased risk of breast lymphomas after postmastectomy implant-based reconstruction, including anaplastic large-cell lymphoma and several B-cell and T-cell non-Hodgkin lymphoma ...

Read Full News

Latest News

Rare Tumor in a Rare Location in Patient With Constipation

Could occupational exposure to sawdust explain this case?

ASTRO: American Society for Radiation Oncology

A Surgical First for Removal of an Appendiceal Neoplasm

Technique deemed safe and feasible for selected patients and better than other minimally invasive approaches

What's Behind the Mysterious Chest Pain in Bladder Cancer Patient?

Cardiomyopathy risks interrupting cancer treatment, worsening prognosis

Cancer Deaths Fall, Cases Rise; Diabetes and Cancer Risk; Vitamin C for Cancer

— News, features, and commentary about cancer-related issues

Benign or Malignant? No Way to Tell Radiologically

Case shows importance of accurate preop diagnosis

Todays Updates

Conference Preview: 2026 GOLD International COPD Conference Tim Smith

HCPLive previews GOLD 2026 in Philadelphia, November 5-6, with sessions on the 2027 GOLD Report, mucus plugging, and exacerbations, plus expert interviews.

7 Pulmonology Headlines You Missed in October

7 Pulmonology Headlines You Missed in October

Nasal mRNA ETH47 Lowers Rhinovirus Load in Asthma Challenge Study

Nasal mRNA ETH47 Lowers Rhinovirus Load in Asthma Challenge Study

Q&A: Why 70% of COPD Goes Undiagnosed, With Alvar Agustí, MD

Q&A: Why 70% of COPD Goes Undiagnosed, With Alvar Agustí, MD

Mucus Plugs in COPD: Prevalence, Exacerbations, Mortality Risk

Mucus Plugs in COPD: Prevalence, Exacerbations, Mortality Risk

Analyzing Inebilizumab’s Durable Benefit in MINT Open-Label Extension Marco Meglio

Richard Nowak, MD, director of the Yale Myasthenia Gravis Clinic and global principal investigator of the MINT trial, discusses open-label extension findings for inebilizumab, a CD19-directed B cell depleting therapy, in generalized myasthenia gravis.

Final Results Reported for EPISOD1 Trial of SOD1-ALS Gene Therapy AMT-162 Marco Meglio

uniQure presented final safety and biomarker results from the discontinued EPISOD1 trial of AMT-162, an investigational gene therapy for SOD1-associated ALS.

Todays Updates

Conference Preview: 2026 GOLD International COPD Conference Tim Smith

HCPLive previews GOLD 2026 in Philadelphia, November 5-6, with sessions on the 2027 GOLD Report, mucus plugging, and exacerbations, plus expert interviews.

7 Pulmonology Headlines You Missed in October

7 Pulmonology Headlines You Missed in October

Nasal mRNA ETH47 Lowers Rhinovirus Load in Asthma Challenge Study

Nasal mRNA ETH47 Lowers Rhinovirus Load in Asthma Challenge Study

Q&A: Why 70% of COPD Goes Undiagnosed, With Alvar Agustí, MD

Q&A: Why 70% of COPD Goes Undiagnosed, With Alvar Agustí, MD

Mucus Plugs in COPD: Prevalence, Exacerbations, Mortality Risk

Mucus Plugs in COPD: Prevalence, Exacerbations, Mortality Risk

Analyzing Inebilizumab’s Durable Benefit in MINT Open-Label Extension Marco Meglio

Richard Nowak, MD, director of the Yale Myasthenia Gravis Clinic and global principal investigator of the MINT trial, discusses open-label extension findings for inebilizumab, a CD19-directed B cell depleting therapy, in generalized myasthenia gravis.

Final Results Reported for EPISOD1 Trial of SOD1-ALS Gene Therapy AMT-162 Marco Meglio

uniQure presented final safety and biomarker results from the discontinued EPISOD1 trial of AMT-162, an investigational gene therapy for SOD1-associated ALS.

Latest News

Could occupational exposure to sawdust explain this case?

Technique deemed safe and feasible for selected patients and better than other minimally invasive approaches

Cardiomyopathy risks interrupting cancer treatment, worsening prognosis

— News, features, and commentary about cancer-related issues

Case shows importance of accurate preop diagnosis

News All Time

Blood Cancer's First New Drug in 29 Years; AI for Mammography? Phase III Myeloma Win

News, features, and commentary about cancer-related issues

More Evidence Ties Microplastics to Lung Cancer

Observational study shows greater microplastic burden in patients with lung malignancy

Nationwide Epinephrine Recall; FBI's Fauci Probe; Bruce Campbell's Cancer

Health news and commentary gathered by MedPage Today staff

9/11's Latest Wave of Cancers, 25 Years On

The health ramifications of the attack persist

Study Warns on Venetoclax in Double-Hit Lymphoma

Excess deaths seen in trial combining the BCL2 inhibitor with intensive initial regimen

Cancer Diagnosis, Then a Stroke; 9/11 Cancer Deaths; 'Grand Slam' Drug and Price

News, features, and commentary about cancer-related issues

No Survival Bump in Metastatic NSCLC With Addition of ADC to Immunotherapy

Non-significant 4-month PFS increase with sacituzumab govitecan-pembrolizumab, no OS benefit

Significant Survival Boost With Novel ADCs in Relapsed Small-Cell Lung Cancer

Death risk cut by 54% with B7-H3-targeting tambotatug pelitecan and risvutatug rezetecan

Local Consolidative Therapy After Dual Immunotherapy Fizzles in Metastatic NSCLC

Overall survival favored nivolumab-ipilimumab alone in LONESTAR trial

Cancer Drug Shortages Continue With No Immediate Path Toward Relief

All responding NCCN members reported shortages, priorities identified but solutions still needed

Brain MRI Surveillance Alone Helps Preserve Cognition in Small Cell Lung Cancer

Omitting prophylactic cranial irradiation led to improved cognitive failure-free survival

Nurse Accused of Exorcism; Death After 8 Hours of Plastic Surgery; Top Cancer Months

Health news and commentary gathered by MedPage Today staff

ROS1-Targeting Lung Cancer Drug Yields 90% Response Rate

Early efficacy among the highest seen in lung cancer, expert says

Drug Combo's Response Rates Top 90% in Small Cell Lung Cancer Trial

Bispecific antibody and ADC together impress in early study

Unprecedented PFS in HER2-Mutant Lung Cancer, but With a Touch of Controversy

Practice-changing median of 14.3 months with T-DXd, but caution over early unfavorable OS trend

Novel Drug Cuts Risk for Death by 44% in Squamous Lung Cancer Trial

If approved, immunotherapy gotistobart could offer a chemo-free option in second-line setting

Recommended News For You

Adjuvant Radiation Boosts High-Risk Bladder Cancer Control

Nuclear missile workers are contracting cancer: They blame the bases

Interleukin-6 may boost prediction of obesity-related cancers

Stem Cell Selection Unneeded for SSc Transplant Therapy?

Decrease seen in in situ breast cancer since 2009

Examines Office-Based Transperineal Prostate Biopsies Methodology.

FDA Approves First CELMoD Drug for Multiple Myeloma

Recommended Articles For You

Connected Transfusion Monitoring: Advancing Safety and Efficacy in Blood Transfusion Practice 

Forecasting Platelet Recovery After Extracorporeal Treatment Through Megakaryocyte Output Dynamics 

Understanding Lymphedema: Symptoms, Causes, and Treatment  

MASLD and Cancer Risk: Pathogenic Links and Clinical Implications Reviewed 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

The Boom in ADHD Coaching Has Few Rules

2.

Implant-based reconstruction linked to increased risk of breast lymphomas

3.

Many patients learn they could have cancer in the emergency department

4.

Patellar Resurfacing in Total Knee Replacement; Patient Messaging Trends

5.

Eliminating the SRC-3 gene in immune cells causes an efficient, long-lasting anti-cancer response.

1.

RNA Vaccines for Therapeutic Oncology: Mechanisms, Clinical Applications, and Future Directions

2.

Care Coordination in Chronic Anemia: Mechanisms, Clinical Implications, and Emerging Strategies

3.

Digital Morphology Systems for Automated Blood-Smear Review

4.

Hematopoietic Reserve Exhaustion in Chronic Blood Disorders

5.

Medical Education Through Multidisciplinary Learning Models for Complex Cancer Care

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Clinical Excellence in Hematology

2.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV

3.

Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL

4.

Clinical Insights in Oncology

5.

INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot